Snus: Difference between revisions
Richardpruen (talk | contribs) Added note on reason for refigereation |
Richardpruen (talk | contribs) →Potential benefits of Snus: Edit passage for clarity |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 21: | Line 21: | ||
* Snus is considered by scientists to be 95%, and possibly closer to 99%, less risky than smoking | * Snus is considered by scientists to be 95%, and possibly closer to 99%, less risky than smoking | ||
* Snus poses no respiratory risk. | * Snus poses no respiratory risk. It cannot cause respiratory diseases, predominantly lung cancer, chronic obstructive pulmonary disease tobacco smoke does, nothing is inhaled. | ||
* Low risk oral nicotine product. | * Low risk oral nicotine product. | ||
* Highly effective way of quitting cigarettes. | * Highly effective way of quitting cigarettes. | ||
| Line 42: | Line 42: | ||
=== Africa === | === Africa === | ||
Snus may be banned in some locations, legal in others. It's use is not common, other more harmful oral tobacco is used more often. | Snus may be banned in some locations, legal in others. It's use is not common, other more harmful oral tobacco [[SLT|(see SLT)]] is used more often. | ||
=== Europe === | === Europe === | ||
| Line 76: | Line 76: | ||
== Studies general information == | == Studies general information == | ||
==== 2024:[https://link.springer.com/epdf/10.1186/s12954-024-01095-7?sharing_token=_1R3Pf6IlmYuu1rCO8WKR2_BpE1tBhCbnbw3BuzI2ROn4zJn13QApxXLzZ1Nm2EMUkgR9kBcTUj-17Nn5d2sQs8mLy3R96OBBGptbTCRJIWB4pPY-WWLKJ0DqqKOq-LBdg_MBr5Q2Y15L5xIyeK8sAjjshzb6jigkC1RlZKharE%3D If there had been no snus in Sweden: the impact of snus on mortality attributable to smoking] ==== | |||
* It is made up by comparisons between observed Swedish data and two scenarios without snus: a group of comparable countries, and, a hypothetical Sweden with no snus use. | |||
* Both comparisons suggest that around 3000 lives per year have been saved by the use of snus in Sweden. | |||
* The potential of snus to reduce smoking-attributable mortality can be elucidated by comparing Swedish data on smoking-attributable mortality with corresponding data from comparable countries with virtually no snus. Switzerland and most EU countries outside Sweden | |||
==== '''2022:''' [https://onlinelibrary.wiley.com/doi/10.1111/eos.12885 The effect of a non-tobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus)] (Sara Alizadehgharib, Anna Lehrkinder, Ali Alshabeeb, Anna-Karin Östberg, Peter Lingström) ==== | ==== '''2022:''' [https://onlinelibrary.wiley.com/doi/10.1111/eos.12885 The effect of a non-tobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus)] (Sara Alizadehgharib, Anna Lehrkinder, Ali Alshabeeb, Anna-Karin Östberg, Peter Lingström) ==== | ||
| Line 187: | Line 193: | ||
===2015: [https://www.sciencedirect.com/science/article/abs/pii/S0955395914002175 The incentives created by a harm reduction approach to smoking cessation: Snus and smoking in Sweden and Finland]=== | ===2015: [https://www.sciencedirect.com/science/article/abs/pii/S0955395914002175 The incentives created by a harm reduction approach to smoking cessation: Snus and smoking in Sweden and Finland]=== | ||
[[ | [[Category:THR product]] | ||
[[ | [[Category:Smoking cessation]] | ||